• +1-646-491-9876
    • +91-20-67278686

    Search

    Candidiasis-Pipeline Review H2 2017

    Candidiasis-Pipeline Review H2 2017

    • Report Code ID: RW00011022679
    • Category Life Sciences
    • No. of Pages 161
    • Publication Month Aug-17
    • Publisher Name Global Markets Direct
    Candidiasis-Pipeline Review, H2 2017

    Summary

    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis-Pipeline Review, H2 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

    Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

    Report Highlights

    Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Candidiasis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 7, 2, 22, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 9 molecules, respectively.

    Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).
    -The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Global Markets Direct Report Coverage 6
    Candidiasis-Overview 7
    Candidiasis-Therapeutics Development 8
    Pipeline Overview 8
    Pipeline by Companies 9
    Pipeline by Universities/Institutes 12
    Products under Development by Companies 13
    Products under Development by Universities/Institutes 16
    Candidiasis-Therapeutics Assessment 17
    Assessment by Target 17
    Assessment by Mechanism of Action 19
    Assessment by Route of Administration 21
    Assessment by Molecule Type 23
    Candidiasis-Companies Involved in Therapeutics Development 25
    Amplyx Pharmaceuticals Inc 25
    Bakker Medical Srl 25
    Beta Pharma Inc 26
    Biomar Microbial Technologies 26
    Bionex Pharmaceuticals LLC 27
    Biosergen AS 27
    Cidara Therapeutics Inc 28
    Dermala Inc 28
    Gedea Biotech AB 29
    General Biologicals Corp 29
    Grupo Ferrer Internacional SA 30
    Hsiri Therapeutics LLC 30
    iCo Therapeutics Inc. 31
    ImmunoClin Corp 31
    Matinas BioPharma Holdings Inc 32
    Nanomerics Ltd 32
    Novabiotics Ltd 33
    NovaDigm Therapeutics Inc 33
    Novartis AG 34
    Onxeo SA 34
    Scynexis Inc 35
    Sealife PHARMA GMBH 35
    Viamet Pharmaceuticals Inc 36
    Visterra Inc 36
    Wellstat Vaccines LLC 37
    Candidiasis-Drug Profiles 38
    (clotrimazole + diclofenac sodium)-Drug Profile 38
    61894700-Drug Profile 39
    AC-17-Drug Profile 40
    amphotericin B-Drug Profile 41
    amphotericin B-Drug Profile 43
    amphotericin B-Drug Profile 49
    Amphotericin B sodium-Drug Profile 50
    Antibody to Target Ece1 for Candidiasis-Drug Profile 52
    APX-001-Drug Profile 53
    APX-001A-Drug Profile 55
    arasertaconazole-Drug Profile 56
    B-4010-Drug Profile 57
    BL-5923-Drug Profile 58
    BSG-005-Drug Profile 59
    candidiasis vaccine-Drug Profile 60
    CD-101-Drug Profile 61
    Cellullar Immunotherapy for Viral Infections and Fungal Infections-Drug Profile 66
    CLX-159-Drug Profile 67
    CSA-13-Drug Profile 68
    Drug for Candidiasis-Drug Profile 70
    Drug for Oral Candidiasis-Drug Profile 71
    Forazoline A-Drug Profile 72
    GA-101-Drug Profile 73
    iCo-010-Drug Profile 74
    interleukin-22-Drug Profile 75
    JSM-11-Drug Profile 76
    KSL-W-Drug Profile 77
    miconazole nitrate-Drug Profile 78
    Monoclonal Antibodies for Candidiasis-Drug Profile 80
    Monoclonal Antibody for Candidiasis-Drug Profile 81
    Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections-Drug Profile 82
    mutanobactin A-Drug Profile 83
    NDV-3-Drug Profile 84
    NDV-3A-Drug Profile 86
    NP-339-Drug Profile 88
    obliquumol-Drug Profile 89
    Occidiofungin-Drug Profile 90
    P-113Du-Drug Profile 91
    P-113Tri-Drug Profile 92
    PAC-113-Drug Profile 93
    Polymers for Clostridium difficile Infections and Candidiasis-Drug Profile 95
    Prof-002-Drug Profile 96
    Recombinant Enzyme for Candidiasis-Drug Profile 97
    Recombinant Peptides for Oropharyngeal Candidiasis-Drug Profile 98
    SCY-078-Drug Profile 99
    SLP-0901-Drug Profile 107
    SLP-0904-Drug Profile 108
    Small Molecule for Bacterial Vaginosis and Candidiasis-Drug Profile 109
    Small Molecule for Candidiasis-Drug Profile 110
    Small Molecule for Fungal Infections-Drug Profile 111
    Small Molecules for Aspergillosis and Candidiasis-Drug Profile 112
    Small Molecules for Candidiasis-Drug Profile 113
    Small Molecules for Candidiasis-Drug Profile 114
    Small Molecules for Candidiasis-Drug Profile 115
    Small Molecules for Fungal Infections-Drug Profile 116
    Small Molecules for Fungal Infections-Drug Profile 117
    Small Molecules for Systemic Candidiasis-Drug Profile 118
    Synthetic Peptide to Inhibit CBL-B for Candidiasis-Drug Profile 119
    Synthetic Peptides for Candidiasis-Drug Profile 120
    Synthetic Peptides for Infections Diseases and Oncology-Drug Profile 121
    TOL-463-Drug Profile 122
    Vaccine to Target Ece1 for Candidiasis-Drug Profile 123
    Vaccine to Target Glucosylceramide for Fungal Infections-Drug Profile 124
    VIS-FNG-Drug Profile 125
    voriconazole-Drug Profile 126
    VT-1129-Drug Profile 127
    VT-1161-Drug Profile 129
    VT-1598-Drug Profile 136
    Candidiasis-Dormant Projects 138
    Candidiasis-Discontinued Products 141
    Candidiasis-Product Development Milestones 142
    Featured News & Press Releases 142
    Appendix 155
    Methodology 155
    Coverage 155
    Secondary Research 155
    Primary Research 155
    Expert Panel Validation 155
    Contact Us 155
    Disclaimer 156

    List of Tables
    Number of Products under Development for Candidiasis, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Candidiasis-Pipeline by Amplyx Pharmaceuticals Inc, H2 2017
    Candidiasis-Pipeline by Bakker Medical Srl, H2 2017
    Candidiasis-Pipeline by Beta Pharma Inc, H2 2017
    Candidiasis-Pipeline by Biomar Microbial Technologies, H2 2017
    Candidiasis-Pipeline by Bionex Pharmaceuticals LLC, H2 2017
    Candidiasis-Pipeline by Biosergen AS, H2 2017
    Candidiasis-Pipeline by Cidara Therapeutics Inc, H2 2017
    Candidiasis-Pipeline by Dermala Inc, H2 2017
    Candidiasis-Pipeline by Gedea Biotech AB, H2 2017
    Candidiasis-Pipeline by General Biologicals Corp, H2 2017
    Candidiasis-Pipeline by Grupo Ferrer Internacional SA, H2 2017
    Candidiasis-Pipeline by Hsiri Therapeutics LLC, H2 2017
    Candidiasis-Pipeline by iCo Therapeutics Inc., H2 2017
    Candidiasis-Pipeline by ImmunoClin Corp, H2 2017
    Candidiasis-Pipeline by Matinas BioPharma Holdings Inc, H2 2017
    Candidiasis-Pipeline by Nanomerics Ltd, H2 2017
    Candidiasis-Pipeline by Novabiotics Ltd, H2 2017
    Candidiasis-Pipeline by NovaDigm Therapeutics Inc, H2 2017
    Candidiasis-Pipeline by Novartis AG, H2 2017
    Candidiasis-Pipeline by Onxeo SA, H2 2017
    Candidiasis-Pipeline by Scynexis Inc, H2 2017
    Candidiasis-Pipeline by Sealife PHARMA GMBH, H2 2017
    Candidiasis-Pipeline by Viamet Pharmaceuticals Inc, H2 2017
    Candidiasis-Pipeline by Visterra Inc, H2 2017
    Candidiasis-Pipeline by Wellstat Vaccines LLC, H2 2017
    Candidiasis-Dormant Projects, H2 2017
    Candidiasis-Dormant Projects, H2 2017 (Contd..1), H2 2017
    Candidiasis-Dormant Projects, H2 2017 (Contd..2), H2 2017
    Candidiasis-Discontinued Products, H2 2017

    List of Figures
    Number of Products under Development for Candidiasis, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Top 10 Routes of Administration, H2 2017
    Number of Products by Stage and Top 10 Routes of Administration, H2 2017
    Number of Products by Top 10 Molecule Types, H2 2017
    Number of Products by Stage and Top 10 Molecule Types, H2 2017
    Amplyx Pharmaceuticals Inc
    Bakker Medical Srl
    Beta Pharma Inc
    Biomar Microbial Technologies
    Bionex Pharmaceuticals LLC
    Biosergen AS
    Cidara Therapeutics Inc
    Dermala Inc
    Gedea Biotech AB
    General Biologicals Corp
    Grupo Ferrer Internacional SA
    Hsiri Therapeutics LLC
    iCo Therapeutics Inc.
    ImmunoClin Corp
    Matinas BioPharma Holdings Inc
    Nanomerics Ltd
    Novabiotics Ltd
    NovaDigm Therapeutics Inc
    Novartis AG
    Onxeo SA
    Scynexis Inc
    Sealife PHARMA GMBH
    Viamet Pharmaceuticals Inc
    Visterra Inc
    Wellstat Vaccines LLC

    Request for Sample

    Report Url https://www.reportsweb.com//candidiasis-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//candidiasis-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//candidiasis-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments